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CHAPTER 1 
WILSON’S DISEASE 
Wilson’s disease (WD) is a human copper (Cu) storage disorder caused by 
mutations in the ATP7B gene located on chromosome 13. 1 Also known as 
hepatolenticular degeneration, its clinical presentation can vary widely, but the 
key features of WD are liver disease and neuropsychiatric disturbances.2-3 The 
hepatic clinical presentation ranges widely from asymptomatic 
hypertransaminasemia and/or hepatomegaly to cirrhosis and acute liver failure. 
The clinical neuropsychiatric symptoms are multiple and for their aspecificity 
sometimes misinterpreted. They include sudden behavioral changes, worsening 
in school performances, inability to carry out activities that need hand-eye 
coordination and modification in handwriting. If WD is not recognized and 
adequately treated, the progression of hepatic and neurologic damage can be 
very rapid. Therefore the prompt detection of this condition is vital. 
Unfortunately, diagnosis remains a challenging patchwork involving clinical, 
laboratory, histological and molecular tools.2 But the first essential step in 
making the diagnosis is to think of it. All WD patients, also pre-symptomatic 
ones, need treatment. The therapeutic success using oral copper chelating agents 
and zinc therapy makes WD one of the few treatable metabolic liver diseases. 
None of the available drugs is side-effect-free. The patient education, adherence 
to therapy and early detection of possible side effects of drugs are the 
cornerstones for a successful treatment.2 
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1.1 GENETICS AND PATHOGENESIS 
Copper is an essential metal that is an important cofactor for many proteins in 
metabolic processes acting as a reactive cofactor in proteins (e.g., connective 
tissue formation, tryptophan synthesis, iron bioavailability, respiration, free 
radical scavenging, pigmentation, and neurotransmitter synthesis) 
However, the same redox properties that make Cu an essential element also 
make it dangerous and potentially damaging to cells.  The average diet provides 
typically 2-5 mg/day (Figure 1).  
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The total daily requirement is about 0.9 mg, so that most dietary copper ends up 
being excreted. In contrast with the iron turnover, which is regulated by 
increasing absorption in deficiency conditions, copper metabolism is regulated 
by increasing the excretion in conditions of overload. Excretion of the majority 
(98%) of copper from the body is mediated by biliary export, indicating that the 
liver plays a central role in the regulation of body copper homeostasis4. Copper 
is absorbed by enterocytes mainly in the duodenum and proximal small intestine 
and transported in the portal circulation in association with albumin and the 
aminoacid histidine to the liver. Her it is avidly removed from the circulation.  
Although copper is virtually absent in the cell under physiological conditions, 
accumulation of the free copper ion is highly toxic due to its capacity to react 
with H2O2 and catalyze the formation of highly reactive hydroxyl radicals that 
can potentially target and destroy any biological molecule.6  Furthermore, excess 
Cu is also toxic because of its ability to displace zinc and other metal cofactors, 
as well as its capacity to ectopically bind to and damage proteins.  
The liver utilizes some copper for metabolic needs, synthesizes and secretes the 
copper-containing protein ceruloplasmin, and excretes excess copper into bile 
(Figure 2).5  
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Copper is imported in the cell via Copper Transporters (CTR) 1 and 2 and in the 
cytoplasm, important scavenger proteins such as metallothionein and glutathione 
protect hepatocytes from its toxic effects. A specific copper chaperone is 
ATOX-1, that delivers copper to ATP7B on the Trans Golgi Network (TGN) in 
the hepatocyte.  
ATP7B maintain a strong interaction with ATOX-1, that influence strongly its 
function (Figure 3). 
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ATP7B, mutated in WD, plays two main roles: one is the incorporation of the 
copper into apoceruloplasmin to synthesize ceruloplasmin at the sinusoidal pole, 
being the protein localised in the TGN; the other is addressing the metal to the 
bile pole, in conditions of excess copper. One of the most specific properties of 
the copper-transporting ATPase ATP7B is its copper-dependent localization. 
Under physiological Cu conditions, Atp7b is synthesized in the endoplasmic 
reticulum and then transported to and retained in the TGN to facilitate Cu 
acquisition by proteins, such as ceruloplasmin, that move through the TGN. An 
increase in hepatocyte Cu levels causes the release of Atp7b from the TGN and 
its translocation to the site of Cu excretion. Therefore, the elimination of excess 
Cu by the liver is tightly linked to the Cu regulated translocation of Atp7b in the 
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polarized hepatocyte.  So all those mutations that affect synthesis of ATP7B, its 
stability, correct localization in the trans-Golgi region and its capacity of traffic 
in condition of intracellular Cu excess, determine toxic accumulation of Cu in 
the hepatocyte with cell damage and consequent release of Cu in the blood that 
hamper other organs.  
The protein structure of ATP7B, with high homology with the Menkes disease 
gene ATP7A, is shown in Figure 46.  
 
Several conserved motifs are required for ATP catalysis: the nucleotide binding 
domain (N-domain), the phosphorylation domain (P-domain) and the actuator 
domain (A-domain). Highly conserved residues are present in these motifs: 
SEHPL in the N-domain, DKTG in the P-domain, and TGE in the A-domain. 
The N-terminal contains six metal-binding domains (MBD1-MBD6, cyan) with 
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conserved CxxC Cu-binding motifs. The transmembrane domain encompasses 
eight transmembrane helices and position of residues that are predicted to be 
involved in Cu-coordination within the membrane. The two leucine motifs 
(1459LL and 1487LL) located at the C-terminal have been shown to be essential 
for endocytosis and/or TGN relocalization from plasma membrane.6 
A sequence of events is needed to the ATP-driven translocation of the copper: 1) 
the binding of the ion, 2) the binding of ATP to the N-domain, 3) ATP 
hydrolysis and phosphorylation of the P-domain, 4) translocation of the target 
ion, and 5) dephosphorylation of the P-domain by the A-domain. ATP7B gene 
mutations can lead to the WD phenotype in different ways.6 
To date, over 800 mutations in ATP7B gene have been reported in the Human 
Genome Mutation Database (http://www.hgmd.org). 7 The sensitivity of 
molecular genetic testing for WD was initially reported as 80%, but subsequent 
studies using more sensitive DNA sequencing methods have raised the 
sensitivity to greater than 98%. Furthermore, cases with a confirmed clinical and 
biochemical diagnosis of WD in whom two ATP7B mutations could not be 
identified have been reported. The possibility of a second WD gene has been 
discussed, but causative mutations in other genes involved in copper 
homeostasis have not yet been identified. 8 WD is caused by mutations which 
can impede every step of the catalytic cycle of ATP7B and the final impact on 
the protein can range from mild to severe depending on which residues are 
affected. The three most-frequent mutations, are p.H1069Q (50-60% in 
10 
 
European and North American patients), p.R778L (40% in East Asian patients), 
and c.2299insC among Caucasians. Mutations with a more-restricted 
distribution include the prevalent c.2007_2013del mutation in Iceland, p.M645R 
in Spain, a distinct 5′ untranslated region c.129_125del mutation in Sardinia, 
c.3402delC in Southern Brazil, p.C271STOP in eastern, western, and southern 
India, and p.Q1399R in the Middle East. It is worth noting the recent report of 
the failure to identify mutant ATP7B alleles in 1 in 10 of a large cohort of 
clinically and biochemically confirmed WD patients. 9 
The most frequent mutations in Italy (that cover 43% of total population) are 
summarized in the following Table 1. (courtesy of Dr. G. Loudianos). 
Mutation Eson Domain % 
p.H1069Q 14 SEHPL 14.8 
c.2532delA 10 Tm4 4.9 
p.R1319X 19 Tm8 4.2 
p.G591D 5 Cu5 4.2 
p.R969Q 13 Tm6 3.8 
c.2304-2305insC 8 Tm4 3.5 
p.G626A 6 Cu6 1.9 
c.3648-3653del 17 Tm6 1.9 
c.-441/-427del Promoter Promoter 1.9 
p.T977M 13 Tm5 1.9 
 
A number of studies, both biological/biochemical and biophysical, characterized 
WD-causing mutations which showed that these mutations may have various 
effects on ATP7B function. The most commonly observed effect is “protein 
misfolding” where ATP7B is retained in endoplasmic reticulum  with a marked 
decrease in protein stability and thus results in the loss of Cu-transport in cells. 
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Some ATP7B variants (comprising most frequent H1069Q, D765N, R778L) 
retain the ability to pump Cu, but fail to achieve right conformation and tend to 
aggregate. As a consequence these ATP7B mutants do not pass the quality 
control, remain held inside the endoplasmic reticulum (ER) and undergo rapid 
degradation, instead of being transported to the sites of excretion of Cu. 10 
Normal ATP7B localization is showed in Figure 5.  
 
1.2 DISEASE MODELING  
The three animal modelpromoters oprf WD—the Long-Evans Cinnamon (LEC) 
rat, the toxic milk mouse and t13he Atp7B knockout (Atp7b–/–) mouse—lose 
ATP7B function. As a result, these animals manifest hepatic Cu accumulation 
due to impaired biliary Cu excretion and low circulating ceruloplasmin levels.5 
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The LEC rat suffers extensive liver damage owing to the Cu accumulation, 
which results from a deletion in the 3′ region of Atp7b that causes loss of 
hepatobiliary Cu excretion capacity. Surprisingly, neither the LEC rat nor the 
Atp7b–/– mice exhibit susceptibility to neurological disease.   
Other animal models mimic Wilson’s disease like the white perch, the fresian 
horse and the north ronaldsay sheep (Figure 6).  
 
The availability of authentic animal models that recapitulate hepatic WD in 
humans, especially the LEC rat, has advanced research in WD. Yet, no mice 
models carrying the most frequent missense mutations of ATP7B (H1069Q or 
R778L) are available. On the other hand, the metabolic pathways of rodents are 
frequently vastly different from those of man, and this is the pivotal reason that 
efforts persist to develop a platform of human cells. 
Hepatocytes obtained via liver biopsy cannot be considered as a good model 
system for WD studies. Indeed, it is extremely difficult to keep human 
hepatocytes from biopsies in culture, as they do not proliferate and rapidly 
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undergo apoptosis. In addition, these cells are generally already damaged at the 
moment of liver biopsy execution.11  
1.3 EPIDEMIOLOGY 
The real prevalence of WD is still debated. The widely cited prevalence figure 
of 1:30,000 with a carrier frequency of 1:90 pre-dates the discovery of ATP7B 
as the disease-causing gene defect and has been questioned. Moreover, based on 
the mass screening of ceruloplasmin levels in dried blood samples from 
children, higher prevalence rates have been found in Japan (1/1,394) and Korea 
(1/3,667), suggesting a significantly higher frequency, ranging from 1:500 to 
1:3000 .13  
Regional clustering of mutations has been very well established. The highest 
incidence of WD reported within a single population is in a mountainous area of 
Crete, in which six out of 90 births were diagnosed as WD patients.14 In France 
recently have been conducted an observational pupulation based study to 
investigate the prevalence WD patients in the nation, concluding that in 2013 
906 prevalent cases were identified, yielding a crude prevalence of 1.5 cases per 
100,000.15  This prevalence is comparable to that reported in other population-
based studies in European countries and to a study using a similar method.  In a 
recent UK population-based genetic study, recent sequencing of the ATP7B 
coding region and adjacent splicing sites in 1,000 apparently healthy neonates 
revealed a heterozygous ATP7B mutation carrier frequency of 1 in 40 and 
predicted a 1 in 7,026 genetic prevalence for WD in the United Kingdom, which 
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is considerably higher than the estimated prevalence of WD. 13 Even if updated 
Italian epidemiological data are missing, WD incidence in the Sardinian 
population (1:2707 live births) remains one of the highest in the world and six 
mutations account for 85% of all WD cases.14 
In Italy an association of patients with WD was founded in 2009 by Salvatore Di 
Lorenzo and Giuditta Scalpi to support research activities on this disorder 
(http://www.malattiadiwilson.org/associazione-chi-siamo.html). Nowadays this 
association accounts for more than 500 affected patients (total extimation from 
drug consumers of 1200 total Italian patients). In the last few years a group of 
scientists involved in WD research field have supported this association 
activities (photo).  
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1.4 CLINICAL FEATURES 
Clinical features associated with symptomatic WD are protean, and it is an 
ultimate great imitator requiring a high index of suspicion for timely diagnosis. 
Although the failure to excrete biliary copper is present from birth, WD 
symptoms generally do not develop until about two years of age, and rarely 
become evident before age of five. Unfortunately, symptoms at any age are 
frequently non-specific. Most of the pediatric WD patients present with liver 
disease, whereas neuropsychiatric symptoms are more common after the age of 
18 years.2 
The hepatic clinical presentation ranges widely from asymptomatic 
hypertransaminasemia and/or fatty liver at ultrasound until cirrhosis or less 
commonly acute liver fail- ure (ALF).1-3 In childhood, the percentages of WD 
patients with hepatic, neurologic or neuropsychiatric presentation can vary 
widely according to expertise of care units and health policy. For example, the 
percentage of WD children presenting with isolated elevated serum 
aminotransferases ranges from 14 to 88%.16 In particular, in Italy where 
aminotransferases serum levels are evaluated in the context of check-up, it is 
more common that WD patients are iden- tified during the first decade of life, 
when liver disease is mild.17,18 There is evidence that copper silently 
accumulates in the liver during childhood, so that alterations in liver function 
tests may precede the onset of symptoms for a considerable time. The acute 
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hepatic presentation is characterized by the presence of liver failure and Coombs 
negative hemolytic anemia. WD is the identified etiology in about 5% of ALF 
patients worldwide.19 
In childhood, presenting symptoms of WD can be sudden behavioral changes, 
worsening in school performances, inability to carry out activities that need 
good hand-eye coordination and modifications in handwriting as the 
micrographia. In approximately 10—25% of WD patients, a psychiatric 
disturbance is the initial clinical presentation, even before the appearance of any 
movement disorder.20 Diagnosis of WD is rarely made during the period in 
which psychiatric symptoms predominate. Although neuropsychiatric symptoms 
are considered secondary to liver damage, neurologic and psychiatric 
manifestations without hepatic involvement have been described also in 
children.20,21 
Nuerologic presentation is more common in adulthood, but it may develop 
insidiously or precipitously, even with  a  stroke-like presentation. 3 Difficulty 
with speech is the most common initial symptom, usually preceding any 
movement disorder. Bradykinesia, facial  grimacing, dystonia,  tremor, and 
rigidity occur, the latter being of ‘lead-pipe’ rather than clasp-knife or cog-wheel 
type. The intention tremor may be initially unilateral then becomes coarse 
generalized, and incapacitating ("wing-beating" tremor).  Features which are not 
usually present in WD are: cortico-spinal or cerebellar signs; abnormalities of 
peripheral nerves, skeletal muscle, or cranial nerves. Neurological features are 
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presenting signs in 40–50% of patients with Wilson’s disease. They tend to 
present later than hepatic manifestations, in childhood but frequently in the third 
decade of life. They can be extremely subtle or may develop rapidly with 
complete disability apparent within a few months. Neurological manifestations 
can be classified as: (1) a dystonic syndrome, (2) akinetic-rigid syndrome akin to 
Parkinson’s disease, (3) pseudosclerosis dominated by tremor, and (4) ataxia. 
Other neurological features include dysarthria, drooling, dysphagia 
(pseudobulbar palsy with a risk of aspiration), a proximal wing-beating tremor, 
dystonia leading to severe contractures, migraines and insomnia, spasticity and 
lack of coordination. Untreated patients continue to deteriorate eventually 
becoming bedbound and dependent in activities of daily living. In patients with 
advanced liver disease, neurological manifestations can be misdiagnosed as 
hepatic encephalopathy.  A Global Assessment Scale for Wilson's Disease  has 
been devised and evaluated as a tool for assessment and monitoring of adult 
neurological patients.22 
Haemolysis may be the initial presentation, sometimes apparently precipitated 
by infection or drugs. There may be a history of a previous undiagnosed 
haemolytic episode in cases presenting with hepatic or neurologic features, and 
haemolysis is prominent in fulminant Wilson’s. 2,3 
Ophthalmic findings include Kayser-Fleischer (KF) rings and sunflower 
cataracts. Both findings are reversible with medical therapy or after liver 
transplantation. It should be pointed out that KF, although very specific for WD, 
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is rarely described in early pediatric ages and in WD children pre- senting with 
clinically asymptomatic hypertransaminasemia, being more frequent (up to 
about 50% of cases) in adolescents and young adults with more severe liver 
disease and/or with neurologic symptoms.18  
Renal tubular abnormalities are frequently found in WD if sought, comprising 
glycosuria, aminoaciduria, renal tubular acidosis, impaired phosphate 
reabsorption, or a full-blown renal Fanconi syndrome, and are the presumed 
consequence of tubular copper deposition. Glomerular dysfunction is less 
frequent, but proteinuria may be exacerbated by penicillamine. Recurrent 
hypokalaemic muscle weakness, hyperoxaluria, renal calculi and 
nephrocalcinosis are uncommon features. Renal abnormalities may become 
manifest post-transplantation as a hepato-renal syndrome. 
Copper-mediated oxidative damage to collagen probably underlies the arthritis 
which occurs in a small number of patients with Wilson’s disease. The 
secondary effects of renal tubular phosphate leak and hepatic osteodystrophy are 
likely to be the cause of the radiologic abnormalities such as rickets or 
osteoporosis which occur in a larger percentage. Skeletal complications appear 
to be more frequent in Asian/Indian patients. 
Infrequent presentations include cardiomyopathy and arrhythmias, gigantism, 
hypoparathyroidism, infertility and repeated miscarriages. 
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1.5 GENOTYPE-PHENOTYPE CORRELATION 
Genotype-phenotype correlation in WD remains a hotly debated topic.16 
Although the high intrafamilial concordance of the WD phenotype suggests that 
mutations and genetic background are the main causes of variability in the WD 
phenotype, the emerging mutation/WD phenotype correlation is poor. Indeed, 
reports linking hepatic and neurologic forms of WD and their early or late onset 
to specific mutations are doubted because of frequent differences between the 
phenotypes of patients who carry the same homozygous mutation, including 
siblings and twins, and by the high variability of the same heterozygous 
mutation.  Based on the best evidence, deletions, frame-shift, nonsense, and 
splicing mutations that produce truncated forms of the protein are often 
associated with severe phenotypes and early disease onset. This can be 
explained by the predicted copper transport impairment caused by such 
mutations that disrupt protein transcription. So fulminant hepatic failure is more 
likely in patients with truncating mutations On the other hand, there is in vitro 
evidence that some missense mutations could allow a residual capacity to export 
copper to the Golgi lumen, where the metal binds to apoceruloplasmin forming 
its stable form ceruloplasmin. Their disease-causing effect on ATP7B protein 
would be the loss of bile pole redistribution capability. The meaning of these 
genotype-linked features can be of interest. So missense mutation seems to 
produce a mild phenotypes with a late presentation. In particular patients with 
common H1069Q mutation tend to present WD later and with neurological 
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disease As previously mentioned, the well known presence of a subset of 
patients with normal or border-line ceruloplasmin could be explained, at least in 
part, with the role played by the genotype. Anyway, one cannot exclude that  the 
differences observed among the patients could be related to factors other than 
the ATP7B genotype, as dietary copper intake and its bioavailability, endocrine 
factors as the influence of the sex hormones, allelic variants of protective genes 
as metallothioneins (Figure 7). Furthermore an additional role of unknown 
modifier genes has been hypothesized. These include polymorphisms in genes: 
apolipoprotein E, prion protein, methylenetetrahydrofolate reductase, copper 
metabolism gene Murr1, antioxidant 1, inhibitor of apoptosis linked to 
chromosome X, as well as those related to iron metabolism, inflammatory 
processes, oxidative stress, and even gender.2  A genetic polymorphism in 
rs738409, in the patatin-like phospholipase domain (PNPLA3), seems to have a 
role in NAFLD and a recent paper also supports its influence in steatosis in WD 
patients.23 
 
21 
 
 
1.6 DIAGNOSIS 
An accurate diagnosis of WD always requires a careful evaluation of the clinical 
symptoms, genetic data, and a combination of tests detecting Cu metabolism 
disruption.2  
The asymptomatic initiation and false unimportance of mild hepatitis and 
moderate psychiatric symptoms and movement disorders that compound the first 
manifestations of WD often delay diagnosis. Consequently, early treatment, 
which is crucial for preventing extensive damage to the liver, the major Cu 
sequestering organ, and irreversible damage to the brain, a principal Cu user, is 
delayed.  In 2003, Ferenci et al21 proposed a diagnostic score for WD, including 
clinical, biochemical, histologic and molecular findings.24 Table 1 shows scoring 
system clarifying for each item the diagnostic validated cutoff in pediatric 
population. It  has been confirmed that WD scoring system may be a reliable 
tool also in children with a mild liver disease.18 
The first step in WD investigation is the measurement of ceruloplasmin serum 
level, which is reduced because of its impaired biosynthesis. Ceruloplasmin is 
an acute-phase reactant, so in presence of histologically active hepatitis, it may 
therefore be falsely normal. Up to 20% of pediatric and adult WD patients show 
normal ceruloplasmin level.2,19 On the contrary, low levels of ceruloplasmin are 
not always indicative of a copper storage disorder because both heterozygotes 
for WD and patients with other disorder may share this feature.16 In particular, 
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ceruloplasmin deficiency has been observed in decompensated liver failure and 
in other pathological conditions, including congenital disorder of 
glycosylation.25 It has been recently demonstrated that also in children the best 
WD diagnostic threshold of ceruloplasmin is 20 mg/dL.18,26 
Serum non-ceruloplasmin bound copper (improperly named serum free copper), 
has been proposed as a diagnostic test but false negatives values are often 
encountered.  
Basal urinary copper (CuB) is another test useful for recognizing WD. The level 
taken as diagnostic of WD in symp- tomatic patients is commonly > 100 μg/24 
hours.2,18 Anyway, in several pediatric series up to 19% of WD patients showed 
urine copper values below the mentioned cutoff. CuB seems to be directly 
correlated with the age at diagnosis of WD, suggesting an accumulation of the 
metal over time. It has been suggested that diagnosis of WD in chil- dren should 
be considered when this test produces the value >40 μg /24/h.18 
Urine copper excretion measurement after a penicillamine challange (CuPCT) is 
considered a diagnostic tool for WD, and it has been commonly considered 
diagnostic when >1600 μg /24 h.3 As suggested by our recent study, CuPCT 
should not be performed in children without symptomatic liver disease, because 
only patients with severe liver damage due to WD had a positive CuPCT.18 
For diagnostic purposes, liver biopsy is only required if the clinical signs and 
non-invasive tests do not provide a final diagnosis or if there is suspect of 
additional liver pathologies.2,3 Hepatic copper accumulation is the hallmark of 
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WD. The liver in WD may demonstrate a wide range of damage patterns. Some 
patients may present almost no detectable microscopic pathology, while others 
display lesions consistent with fulminant hepatitis or acute liver failure. Most 
liver biopsy specimens show moderate to severe steatosis, variable degree of 
portal and/or lobular inflammation, and fibrosis eventually progressing to 
cirrhosis. Additional findings include liver cell degeneration and ballooning, 
Mallory hyaline bodies, liver cell necrosis, and glycogenation of periportal 
hepatocytic nuclei. None of the above lesions are specific for 
Wilson disease and should be interpreted in a wider medical context and 
particular clinical setting. 27 
Qualitative measurements of hepatic copper content, such as stains for copper or 
copper-associated proteins (e.g. orcein, rhodanine, rubeanic acid stain), are 
useful but unreliable tools for diagnosis or exclusion of WD. Liver copper 
content greater than 250 μg /g dry weight is considered diag- nostic for WD.3 It 
is well known that in long standing cholestatic disorders, hepatic copper content 
may also be increased above this level. Values < 40—50 μg /g dry weight 
exclude diagnosis of WD.2 Hepatic copper threshold value has been criticized as 
being too high. The problem to apply a lower threshold is linked mainly to the 
fact that the concentration of hepatic copper in heterozygotes is frequently 
higher than normal.3,18 
Establishing a diagnosis of fulminant WD can be difficult because KF rings may 
not be present and parameters of copper metabolism are neither specific nor 
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diagnostic.28 Serum alkaline phosphatase levels are disproportionately low, 
while total bilirubin is disproportionately high due to concomitant rise of 
indirect bilirubin from copper induced haemolysis. Some series supported that 
values of less than 2.0 for the alkaline phosphatase (AP)-total bilirubin (TB) 
ratio and greater than 4.0 for the aspartate (AST)-alanine transaminase (ALT) 
ratio provide a good sensitivity and specificity in identifying fulminant hepatic 
failure caused by WD from other etiologies.29 However, a pediatric study 
showed that differentiation from other causes of fulminant liver failure in 
children on the basis of these biochemical parameters was not sufficient.28 In 
particular, in children, AP levels are higher as they originate also from the bone 
component.  
Finally in Wilson’s disease, computed tomography of the brain will show 
increased density around the basal ganglia, whereas magnetic resonance (MR) 
imaging may be more sensitive and will usually reveal hyperintensity on T2-
weighted MR imaging of the basal ganglia.3 Other features include the ‘face of 
the giant panda’ sign and hyperintensities in the tectal-plate, central pons and the 
brainstem. Abnormal brain imaging may even be present in some individuals 
prior to the onset of symptoms.3 Figure 8 summarize diagnostic approach for 
WD proposed by recent ESPGHAN guidelines.  
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Table 2: Diagnostic score for Wilson Disease. (Modified from Ferenci et al)  
Laboratory tests  Clinical symptoms and signs  
Serum ceruloplasmin  Kayser-Fleisher rings  
Normal (>20 mg/dl) 0 Present 1 
10-20 mg/dl 1 Absent 0 
< 10 mg/dl 2   
Urinary copper (in absence of 
acute hepatitis) 
 Neurologic involvement   
Normal (< 40 μg/24h) 0 Severe 2 
1-2 x ULN* (40-80 μg/24 h) 1 Mild 1 
>2 x ULN* (> 80 μg/24 h) 2 Absent 0 
Normal, but > 5 x ULN*  
(>200 μg/24 h after penicillamine 
challenge) 
2   
Liver copper (in absence of 
cholestasis) 
 Coombs negative hemolytic anemia  
Normal (<50 μg/g dry weight) -1 Present 1 
< 5 x ULN* (50-250 μg/g dry 
weight) 
1 Absent 0 
< 5 x ULN* (>250 μg/g dry 
weight) 
2   
Rhodanine stain   Mutation analysis  
Absent 0 2 chromosome mutations 4 
Present  1 1 chromosome mutation 1 
  No mutations detected 0 
Assessment of the WD-diagnostic score: 4 or more=affected by WD; 2-3= WD likely, do 
more investigations; 0-1= WD unlikely; *ULN: upper limit of normal 
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1.7 MOLECULAR ANALYSIS AND SIBILING SCREENING 
From a genetic point of view, the diagnosis of WD is based on the identification 
of two disease causing mutations. It should be performed for individuals in 
whom the diagnosis is difficult to establish by clinical and biochemical testing 
or to screen asymptomatic sibling of patient with WD.3 A further indication is in 
case of WD-related fulminant hepatitis, when the conventional diagnostic tools 
are unre- liable. Detection of mutations on both chromosomes allows a 
definitive diagnosis of WD, whereas the diagnosis cannot be excluded because 
of their absence. 
Sibling screening is mandatory when a new case of WD is diagnosed.30 This 
should include clinical examination, liver function tests, biochemical tests of 
copper metabolism and mutational analysis if the proband’s mutations are 
known. If mutational analysis is not available, biochemical testing should be 
delayed until after six months of age, because ceruloplasmin levels are low in 
the newborn. In definitive, despite the availability of multiple tools, diagnosis of 
WD is very challenging in childhood. The first essential in making the diagnosis 
is to think of it and an high suspicion index is required. 
Newborn and childhood  population screening has been considered by various 
groups. WD does fulfill some criteria for population screening: it is sufficiently 
common, serious, and treatable. There are 2 problems: first, the uncertain 
prognosis of the genetically diagnosed neonate, and second, the robustness of 
available methodology. The low neonatal ceruloplasmin in neonates makes 
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detection of WD very difficult. On the other hand mutation screening would 
only be effective in populations with a single common mutation.2,30  Such 
screening programs pre-suppose knowledge of the prognosis of the 
genotypically affected individual, which we do not have. Whilst it is appropriate 
to test the siblings of a child with active disease, it is not appropriate to bestow a 
diagnosis whose implications we are unsure about. This is a topic which requires 
further research and pilot studies. 
 
1.8 WILSON DISEASE MIMIC DISORDERS 
There are some inherited disorders other than Wilson disease that impair directly 
or indirectly hepatic copper metabolism and look-alike Wilson disease. These 
conditions determine disease phenotypes and/or biochemical abnormalities that 
may mimic Wilson disease, making the appropriate diagnosis extremely 
challenging.  
Congenital disorders of glycosilation (CDG) are inherited metabolic disease 
caused by abnormalities in proteins glycosilation.   
Some CDG subtypes share with Wilson Disease not only liver and brain 
involvement, but also  partial or complete Wilson phenocopy (low serum copper 
and/or ceruloplasmin, copper accumulation on liver biopsy, increased urinary 
copper excretion). Liver involvement is present in about 22 % of CDG types. 
The CDG types with predominant or isolated liver involvement comprise MPI-
CDG, CCDC115-CDG, TMEM199-CDG, and ATP6AP1. Coagulopathy may 
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occur independently from the severity of liver dysfunction and is caused by 
abnormal glycosilation of clotting factors. CDG testing (transferrin and apoCIII 
IEF, CDG panel genetic testing) should be performed in patients diagnosed as 
affected by Wilson Disease but in whom ATP7b mutations are not found. The 
main CDG subtypes, that could be misdiagnosed as Wilson Disease, are the 
TMEM199-CDG, CCDC115-CDG, ATP6AP1-CDG, PMM2-CDG, and COG2-
CDG. In particular, for TMEM199-CDG and CDG type IIx  a correct 
differential diagnosis of WD may be challenging because  the patients may show 
only an isolated liver disease in the absence of typical CDG phenotype.31,32 
Sometimes further investigations for CDG can be triggered by the presence of 
coagulopathy not explained by the liver disease.  In CDG it has been 
hypothesized that copper abnormalities are linked to disturbed biosynthesis of 
the glycoprotein ceruloplasmin, as observed in aceruloplasminemic mice model. 
MEDNIK syndrome (Mental retardation, Enteropathy, Deafness (sensorineural 
hearing loss), peripheral Neuropathy, lamellar and erythrodermic Ichtyosis, 
Keratodermia) is a severe neurocutaneous disorder. It is a genetic disorder, 
included in the family of adaptinopathies, caused by mutations to the AP1S1 
gene, on chromosome 7q22.1. 33,34 It determines an improper function and 
trafficking of copper ATPases resulting in less retention in the trans-Golgi and 
excess copper in the plasma membrane. As for disease phenotype some of the 
neurological, cutaneous and skeletal symptoms are similar, but milder than those 
of Menkes disease. 33 On the other hand, hepatopathy and brain MRI features are 
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reminiscent of Wilson disease. In particular, liver involvement in this disorder, 
not clearly considered as main hallmark of disease phenotype, is a common 
finding in affected patients. They show hepatomegaly, intractable itching, liver 
steatosis, elevation of transaminases and bile acids. As for copper metabolism 
parameters, patients show, as Wilson’s disease patients, low levels of 
ceruloplasmin, increased urinary copper excretion and liver copper content.34  
At brain MRI, patients have basal ganglia involvement with bilateral 
symmetrical hyperintensities in caudate nuclei and putamina at T2-weighted 
images, a pattern similar but milder than in Wilson’s disease.  Differently from 
Wilson’s disease cerebral atrophy is a common finding. No patients have 
Kayser-Fleisher ring. Considering similarities to Wilson’s disease, one patient 
has been treated with zinc acetate that successfully reduces liver copper 
overload and cholstasis, with clear improvement of the patient’s behaviour.34 
Manganese overload could determine a neurologic and liver dysfunction 
resembling Wilson’s disease. 35 The first inborn error of Mn metabolism has 
been identified by Tuschl et al and called hypermanganesemia. It is an 
autosomal recessive disorder, with a pleomorphic phenotype, characterized by 
an early-onset generalized dystonia (before 10 years old), polycythemia (with 
depleted iron stores and low ferritin), characteristic brain MRI findings in the 
basal ganglia  and chronic liver disease (hepatic disfunction may vary among 
members of the same family).36  It is due to mutations in one of the solute carrier 
(SLC) SLC30A10 gene (Znt10), encoding a Mn transporter, highly expressed in 
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the liver and brain, including in the basal ganglia. Patients with mutations in 
SLC30A10 have not abnormalities in copper urinary excretion, but high blood 
levels of manganese (exceed 2000 nmol/L; normal <320 nmol/L). 37,38 Recently, 
it has been described a Mn/zinc transporter defect caused by mutations in 
SLC39A14 (ZYP 14), also linked to a progressive childhood-onset parkinsonism 
dystonia, probably linked to an  alterated hepatic uptake (and hence biliary 
excretion) of manganese, leading to symptoms caused by excessively high 
manganese levels in the brain.39  Additionally, in a recent paper, Nagappa et al 
described an Indian cohort of patients with the so called “non-Wilsonian 
hepatolenticular degeneration” and a brain MRI that showed hyperintensity on 
T1 and hyper-hypointensyty on T2, in the “absence of an “acquired” liver 
disease, assuming a defect of manganese metabolism, also in absence of 
polycitemia.40 Therefore, as for Wilson's disease, manganese blood levels should 
be routinely tested alongside copper and ceruloplasmin in the initial diagnostic 
work-up of patients with young-onset generalized dystonia. 
Aceruloplasminemia could be as a link between copper and iron metabolism.  
Firstly described in 1987 by Miyaima et al, it is an autosomal recessive disorder 
of iron homeostasis due to loss-of function mutations in the ceruloplasmin gene. 
41 Ceruloplasmin determines the rate of iron efflux from cells with 
mobilizable iron stores. Affected individuals may present in adulthood with 
evidence of hepatic iron overload, diabetes, peripheral retinal degeneration, 
dystonia, dementia or dysarthria. Laboratory studies demonstrate: the triad 
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microcytic anemia, elevated serum ferritin and a complete absence of serum 
ceruloplasmin ferroxidase activity. Consistent with the observed neurologic 
findings, MRI reveals iron accumulation within the basal ganglia. Histologic 
studies detect abundant iron in reticuloendothelial cells of the liver and spleen, 
in beta cells of the pancreas, and in astrocytes and neurons throughout the 
central nervous system.41,42  
Finally in chronic cholestatic conditions the normal physiological secretion of 
copper into the bile is blocked leading to lysosomal accumulation of copper, as 
in late WD. Furthermore, patients with MDR3 deficiency (previously known as 
progressive familial intrahepatic cholestasis 3 or PFIC 3), primary sclerosing 
cholangitis (PSC), and primary biliary cholestasis (PBC) have been found to 
have significantly elevated hepatic copper concentrations and may share some 
histopathological features with WD.43  Generally, however in these conditions, 
liver copper content does not reach levels as high as that observed in WD.  
Occasional patients with MDR3 deficiency have been described as having 
increased liver copper content and also abnormal urinary copper excretion, and 
sometimes low serum ceruloplasmin levels.43 Therefore, the diagnosis of MDR3 
deficiency may be challenging in the absence of genetic analysis to exclude 
WD. While some of the histologic findings in MDR3 deficiency (mild chronic 
hepatitis, steatosis, glycogenated nuclei and Mallory-Denk bodies) are seen in 
WD, none of them is specific to either disease. Immunohistochemical staining 
for the MDR3 on bile canalicular membranes is negative in MDR3 deficiency 
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but intact in WD. 44,45 Liver biopsy preceding therapy, both in WD and MDR3 
deficiency, can show dense lysosomal deposits due to aggregates of copper and 
copper binding proteins such as metallothioneins. Moreover, it has been recently 
found that similar to individuals with WD, patients with bile salt export pump 
(BSEP) deficiency or MDR3 deficiency can have elevated hepatic copper 
concentrations sufficient to impair nuclear receptor activity.46
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1.9 TREATMENT & OUTCOME  
The overall therapeutic aim for WD is the generation of a negative copper 
balance. Today this can be achieved either by liver transplantation, which 
phenotypically corrects the gene defect in the liver, or by medical therapy. 
Obviously liver transplantation is a treatment option for patients with severe 
life-threatening conditions in whom the window for medical treatment is not 
wide enough. It cannot be proposed as a therapeutic strategy, given the high rate 
of complications and the need for immunosuppressive therapy for life. For all 
other WD patients, lifelong medical therapy is indicated. Conventional medical 
therapies for children comprise treatment with either copper chelators 
(penicillamine or trientine) and zinc (Table 2).2,3 Chelators mobilize intracellular 
copper into the circulation and enhance urinary excretion of copper, while zinc 
acts inducing copper-binding metallothione in both in enterocytes, reducing 
metal intestinal absorption into portal circulation, and in hepatocytes, reducing 
the damaging effects of free liver copper. 
Today, it has been recently supported that, regardless of the drug used, 
appropriately treated patients with WD have an excellent long-term prognosis, 
with a survival probability not differing from the general age and sex-matched 
population (Figure 4).47 It has been described that more than 30% of WD 
patients adequately treated since childhood with the available drugs do not 
exhibit complete normalization of liver enzymes but have a good quality of life 
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and a favourable outcome.47 On the other hand, regardless of type of treatment, 
it has been described that a poor compliance or discontinuation of medical 
therapy is associated with high risk of hepatic decompensation requiring even 
liver transplantation.2,3 
American3 and European48 guidelines provide an useful therapeutic support 
even if many points remain unclarified for pediatric patients. There is a lack of 
high quality evidence to compare the relative treatment effects of the available 
drugs in children. 
For pre-symptomatic patients, who include the subjects identified following 
family screening before the onset of symptoms, the recommended approach is 
therapy with zinc, considered its proven efficacy and safety profile.49 
Initial treatment for patients with significant chronic liver disease (portal 
hypertension, cirrhosis etc.) should include always a chelating agent.50 
Penicillamine and trientine have many beneficial effects but also multiple 
potential toxicities, which may require discontinuation in up to 30% of cases 
(Figure 5).2,3 In particular in patients with neurological symptoms chelators 
should be introduced gradually over time to avoid rapid deterioration of 
neurological function.3 In contrast to copper chelators, zinc has a lower toxicity 
and rarely leads to worsening in neurological symptoms. Its efficacy is contested 
especially in adult patients with liver disease, when applied for very long 
periods.50  Pediatric experience is totally different from that concerning adult 
patients. In particular, in patients with mild liver disease, diagnosed in 
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childhood, zinc monotherapy seems to be effective in controlling WD related 
liver disease both as first-line and as maintenance treatment, with a low rate of 
adverse events. 49  In patient presenting with neurologic or psychiatric signs, 
zinc may have a role as a first line therapy as it is not associated with 
neurological deterioration.2,3 As maintenance therapy after the induction phase 
with chelators, the patients with a good control of the disease may be treated 
with lower doses of chelators or be shifted to zinc.3 
Initial old studies by George Brewer with another drug tetrathiomolybdate, 
showed a very rapid reduction of free copper levels and significantly less 
neurological deterioration than with use of a chelator, were a substantial step 
forward. 51 Tetrathiomolybdate, a strong decoppering agent, recently has been 
licensed in Europe. Consisting of a molybdenum molecule surrounded by four 
sulfhydryl groups, TTM forms a tripartite complex with almost any protein. 
Tetrathiomolybdate increases the Cu excreted in the stool by binding the metal 
in food and in gastric juices, and at the same time by slowing the entrance of Cu 
into tissues and organs that enables the formation of a complex between the 
metal and albumin in the blood, which is slowly metabolized by the liver and 
eliminated through the bile.  It was succesfully proposed the use of bis-choline 
tetrathiomolybdate (WTX101), a stable form of tetrathiomolybdate, a for 
patients with Wilson’s disease who cannot be adequately treated with chelators 
or zinc. This phase 2 study shows that after 24 weeks of treatment, patients also 
had a large improvement in neurological symptoms. In this study, the dosage of 
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WTX101 was variable and needed to be individually titrated. Before this drug 
can be used more generally, more specific guidelines are needed.52 
The adherence to a life-long therapeutic regimen may be poor, mainly in the 
teenage age. Therefore, the patients should be checked periodically to supervise 
the occurrence of side effects and to assess the adherence to the prescribed 
regimens. 
Table 3: Drugs used in the treatment of  children with Wilson Disease in 
Italy 
Drug Dosage and timing Efficacy parameters 
Penicillamine - 20mg/kg/die divided in 2-4 divided 
dosages  
- in young adults 1000 mg/die (maximum 
1500 mg/die) in 2-4 divided dosages 
-  maintenance dose 10-20mg/kg/die up 
to 750-1000 mg/day in 2 divided 
dosages  
- 1 h before or 2-3 hours after meals 
- Supplemental pyridoxine should be 
provided (25-50 mg/day) 
- Reduce dose during pregnancy  
- Reduce dose for surgery  to promote 
wound-healing 
Urinary copper: around 1000 μg 
(16 μmol) after starting 
treatment 
Urinary copper: 200-500 μg/24 h 
(3-8 μmol/24 h) on maintenance 
treatment 
 
Trientine - 20mg/kg/die divided in 2-3 doses  
- maintenance dose 900-2700 mg/day 
- 1 h before or 2-3 h after meals 
- Reduce dose during pregnancy 
- Reduce dose for surgery  to promote 
wound-healing 
Urinary copper: around 1000 μg 
(16 μmol) after starting 
treatment 
Urinary copper: 200-500 μg/24 h 
(3-8 μmol/24 h) on maintenance 
treatment 
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Zinc salts 
 
 
 
 
- Dosage: 
Elemental zinc (acetate) 
Age < 6 yrs: 25 mg twice daily  
6 – 16 yrs  with weight < 50 kg: 25 mg three 
times daily  
Age > 16 yrs or weight > 50 kg: 50 mg three 
times daily 
Zinc sulphate 
Age < 6 yrs: 100 mg twice daily  
6 – 16 yrs  with weight < 50 kg: 100 mg three 
times daily  
Age > 16 yrs or weight > 50 kg: 200 mg three 
times daily 
- 1 h before or 2-3 h after meals 
- No dosage reduction for surgery and 
pregnancy 
 
Urinary copper: > 75 μg/24 h 
(1.2 μmol) on maintenance 
treatment 
Urinary zinc: >2 mg/24 h on 
maintenance treatment 
Serum zinc: > 1250 μg/l on 
maintenance treatment 
 
 
1.10 NEW THERAPEUTC STRATEGIES 
New therapeutic strategies are based on: correction of dysfunctional ATP7B, 
gene therapy and cell therapy. 53 
Correction of ATP7B is obtained mainly manipulating their translocation from 
the ER to ensure correct localization in the cell. This could be beneficial for a 
sizable portion of WD patients affected by mutations resulting in aberrant 
protein products that frequently exhibit residual Cu-transporting activity but 
which undergo strong degradation due to misfolding and retention within the 
endoplasmic reticulum (ER). It is worth noting that most of ATP7B mutations  
have this property, belonging to missense (58%) or small deletion/insertion 
(27%) categories.10 
Considering these similarities, several labs have tested the potential of ΔF508-
cystic fibrosis correctors, such as curcumin and 4-phenylbutyrate (4PBA), for 
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ATP7B mutant rescue. Both correctors were demonstrated as capable of 
reducing degradation of ATP7B mutants expressed in HEK293 cells 14; 
however, curcumin failed to do so in HLCs expressing the R778L variant of 
ATP7B 11. It remains unclear to what extent these drugs rescue localization and 
function of ATP7B mutant 14. Curcumin has been reported to correct 
localization of ATP7B-R778L and to facilitate Cu efflux from patient-derived 
HLCs. 54,55 
On the other hand, a recent analysis of global gene expression in hepatic HepG2 
cell lines expressing either wild type ATP7B or ATP7B-H1069Q mutant 
revealed that suppression of p38 and JNK reduces retention of H1069Q (Figure 
8) and a few other ATP7B mutants in the ER, inhibits their degradation, and 
facilitates Cu excretion from mutant-expressing cells (Figure 9).56  
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Therefore, p38 and JNK have become attractive targets for exploring approaches 
to mutant correction. Indeed, it has been recently reported57 that p38 and JNK 
control a cluster of ER quality control genes that promote ATP7B-H1069Q 
degradation. This cluster comprises a well-known chaperone, heat shock protein 
70 (HSP70), whose silencing protects the ATP7B mutant from degradation and 
facilitates its export from the ER to the Golgi complex where ATP7B normally 
works.  
Finally the current pharmacological treatments have largely failed in rescue of 
Cu homeostasis in WD patients with acute liver failure, leaving LT as the only 
viable option for treatment. A recent study using the lec rat model of WD 
proffered an extra option for such patients.58 The authors investigated the 
therapeutic value of methanobactin (MB), a peptide produced by Methylosinus 
trichosporium which has an extremely high affinity for Cu. Short-term MB 
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treatment efficiently reversed liver damage in the acute stages of liver Cu 
accumulation, as compared with that seen in untreated ATP7B-deficient rats. 
This beneficial effect was associated with depletion of Cu from sites of 
intracellular deposition, in particular from the mitochondria. Interestingly, the 
regular Cu chelators penicillamine and tetrathiomolybdate failed to clean toxic 
metal from the mitochondrial stores. As a consequence, MB treatment prevented 
hepatocyte death and the subsequent liver failure, elongating the life span of the 
rodent model. These findings suggest that MB has potential as a new therapeutic 
agent for the treatment of acute WD. 
Findings from another recent study have suggested that liver X receptor 
(LXR)/retinoid X receptor agonist may be used to combat Cu toxicity in WD.59 
This approach does not require Cu chelation. Careful investigation of the 
transcriptional and metabolic changes in samples from WD patients and Atp7b-
/- mice revealed dysregulation of LXR as one of the key events in the 
pathogenesis of WD. Treatment with the LXR agonist T0901317 improved 
disease manifestations in the Atp7b-/- mice despite substantial Cu overload. 
Moreover, liver fibrosis and inflammation significantly decreased in LXR 
agonist-treated animals, while lipid profiles normalized and liver function and 
histology improved. Thus, the potential of T0901317 for WD cure is likely to be 
further explored. 
Cell therapy, as well as gene therapy, targets the liver, which does not express 
functional ATP7B protein. The fundamental purpose of cell/gene therapy in WD 
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is to restore ATP7B-mediated hepatobiliary Cu excretion.59 Cell therapy in WD 
seems feasible because transplanted hepatocytes can integrate in liver 
parenchyma and restore deficient functions, including the transport of Cu into 
bile. The availability of authentic animal models that recapitulate hepatic WD, 
especially the LEC rat, has advanced cell transplantation research in WD. It was 
through this animal model that it was found necessary to repopulate at least 
30%–40% of the liver with healthy hepatocytes in order to achieve sufficient Cu 
clearance and therapeutic benefits.  Extrahepatic cell therapy using engineering 
applications (i.e. transplantation of liver tissue into small intestine or the 
abdominal cavity) is currently considered insufficient because Cu removal 
requires an intact bile excretion system. 60 Thus, in the case of either cell or gene 
therapy in WD, the rationale for targeting the liver first and foremost is based on 
the physiological restriction of ATP7B expression to hepatocytes as well as the 
availability of mechanisms required for the transfer of Cu ions by ATP7B into 
the bile canaliculus, the entry of Cu into bile ducts and intestines, and the 
elimination of Cu from the body.61 Fortunately, transplantation studies using 
donor cells have confirmed the ability for biliary excretion, providing the first 
clue that biliary Cu transport is a feasible target for cell therapy in WD.62   
IPSC-derived HLCs can repopulate the liver but they support only some 
hepatocyte functions, which are restricted to fetal-like stages.11 Therefore, 
transplanted cells can proliferate in the presence of native cells, having a low 
rate of proliferation. This happens when native liver cells have extensive DNA 
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damage (as induced by toxins, ischemia and/or hepatectomy). As such, the 
nature of preconditioning regimens suitable for clinical applications in people 
will require substantial additional intervention to address chemical exposure 
(e.g. retorsine) or ablative procedures (e.g. partial hepatectomy), will be 
undesirable in the setting of existing liver injury in WD. The ability of 
transplanted HLCs to express ATP7B was evaluated in liver of LEC mice, in 
which the transplanted cells did not increase in number over an observational 
period of several months.63 Therefore, despite adequate engraftment of 
transplanted cells into liver, the gradual onset of liver repopulation over a very 
long period implies that therapeutic correction in WD will require significant 
time.60  
Gene therapy aims to correct the defect in native hepatocytes by providing 
healthy copies of ATP7B via introduction of a transgene by vectors capable of 
indefinitely integrating and/or persisting in cells. The proof-of-principle for gene 
therapy in WD came from adenoviral and lentiviral vector expression of ATP7B 
in the liver of LEC rats and murine models of WD, which achieved transient 
correction of Cu excretion and incorporation of Cu into ceruloplasmin.64 
Recently, these initial observations were confirmed with an adeno-associated 
vector serotype 8 (AAV8) encoding the human ATP7B cDNA placed under 
control of the liver-specific α1-antitripsin promoter (AAV8-AAT-ATP7B). 
Expression of AAV8-AAT-ATP7B in ATP7B-deficient mice resulted in 
reductions of serum transaminases and urinary Cu excretion, normalization of 
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serum ceruloplasmin levels, and recovery of physiological biliary Cu 
excretion.64 This study showed a potential of AAV8-AAT-ATP7B-mediated 
gene therapy in a clinically relevant animal model of WD, providing a solid 
background for future translational studies. AAV-mediated gene therapy should 
allow ATP7B to be permanently expressed in WD patient liver and, hence, 
would eliminate a need for lifelong intake of Cu-reducing drugs. On the other 
hand, such risks as immune response, tumor biogenesis and poor integration into 
damaged cells have to be weighted before AAV-mediated gene transfer therapy 
65and will be a critical component of the repertoire of WD treatments. 
Furthermore, studies investigating the fate of genetically modified native cells 
within the liver in WD are still required. It has yet to be determined whether 
targeting will be effective for subsets of undamaged native cells or putative 
endogenous stem/progenitor cells that have not been affected by Cu-induced 
damage.60 
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CHAPTER 2 
AIMS  OF  RESEARCH PROJECT 
As we previously descuss, while available drugs allow for sufficient control of 
the symptoms, they do not cure WD. Thus, there remains a clear need for novel 
treatment strategies aimed at curing WD through correction of the cellular 
defect.  
Aims of our study was:  
1. To create a new in vitro WD platform derived from patients cells to 
explore pathogenic mechanism linked to H1069Q-ATP7B mutants  
2. To found new active compounds using the hypothesis driven strategy 
3. To found new active compounds using the the high- throughput screening 
4. From bench to bedside: to develop a clinical trial 
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CHAPTER 3 
 A NEW IN VITRO WD PLATFORM DERIVED FROM PATIENTS 
CELLS TO EXPLORE PATHOGENIC MECHANISM LINKED TO 
H069Q-ATP7B MUTANTS  
The recent development of stem cell-derived hepatocyte-like cells (HLCs) opens 
new avenues for gene- and/or drug-based therapy to treat liver diseases. This 
new “in vitro model” better mimics patient cell biology. HLCs can be fairly 
easily derived from induced pluripotent stem cells (iPSCs) that are generated 
through the reprogramming of human fibroblasts. iPSCs can be indefinitely 
expanded in vitro and differentiated in all cells types derived from the three 
germ layers. Thus, iPSC technology features the potential benefits of embryonic 
stem cells while addressing their major ethical and scientific concerns: embryo 
destruction and immune-incompatibility. In this manner, human iPSCs represent 
an unlimited source of human hepatocytes for translational research and hold 
great promise for drug screening and liver disease modeling in particular.  
In this context, it seems particularly helpful to obtain HLCs from WD patients. 
It is important to underline that in addition to their HLC differentiation capacity, 
iPSCs can differentiate into neurons, providing a serious advantage in studying 
whether and how certain ATP7B mutations contribute to neurologic dysfunction 
in WD patients. But in this project we don’t consider neurons differentiation.  
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GENERATION, CHARACTERIZATION AND HEPATIC DIFFERENTIATION 
OF WD AND CONTROL IPSCs 
To generate iPSCs we obtained primary fibroblasts from skin biopsies of two 
WD patient carrying the H1069Q mutation (H1069Q/H1069Q, patient # 1 and # 
2) and his mother and brother (respectively) as a control (WT/H1069Q) 
(henceforth referred to as patient and control). iPSCs were generated using an 
integration-free method by transfecting episomal plasmid vectors into primary 
fibroblasts, thus avoiding genetic integration in the reprogrammed cells. iPSC-
like colonies emerged three weeks after transfection and their stemness was 
assessed by immunofluorescence for Nanog and Oct4 positivity  
Figure 9. Generation of iPSCs from human fibroblasts heterozygous and 
homozygous for th H1069Q mutation of ATP7B 
 
Two clones of each WD and control iPSCs were subjected to cytological 
analysis and showed a normal karyotype (Fig. 9B). These clones were adapted 
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to grow in feeder-free conditions to avoid feeder contamination during 
differentiation and then analyzed for the maintenance of stemness after multiple 
passages (≥15). The expression of pluripotent stem cell marker, Oct4 and 
Nanog, was assessed by immunofluorescence microscopy (Fig. 9C).  
Next, we differentiated patient and control iPSCs into HLCs using a previously 
established protocol that mimics three developmental stages of liver 
development: definitive endoderm, hepatic progenitors and hepatocyte-like 
cells. The expression of markers corresponding to the three phases was verified 
by immunofluorescence microscopy and quantitative real-time PCR.  
 
ATP7B EXPRESSION IN HLCS FROM PATIENT AND CONTROL iPSCs 
We analyzed the expression of ATP7B in HLCs derived from patient and 
control iPSCs in all differentiation experiments by immunofluorescence and 
found that both in control and patient HLCs 30–40% of the total cell population 
was positive for the protein (Figure 10).  
 
Figure 10. Immunofluorescence analysis of the expression of ATP7B in 
HLCs derived from control and patient iPSCs. 
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LOCALIZATION OF ATP7B 
To assess the localization of ATP7B in patient and control HLCs, we first used 
confocal immunofluorescence analysis. In HLCs from the patient significant 
amounts of ATP7B-H1069Q also were found in the Golgi and at moderate 
levels in the ER (Fig. 11). This was surprising considering that when the 
ATP7B-H1069Q mutant is expressed in heterologous as well as in hepatic cells 
it resides almost exclusively in the ER, while only very small amounts of this 
mutant protein can be found in the distal compartments of biosynthetic pathway.  
Figure 11. Confocal immunofluorescence analysis of HLCs immunolabeled 
for ATP7B and Golgin 97 (upper panels) or KDEL containing proteins 
(lower panels) as markers of Golgi complex and ER, respectively 
.  
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The subcellular distribution of ATP7B was therefore further investigated with 
immuno-gold electron microscopy (EM). As expected, in control HLCs ATP7B 
was preferentially localized along the membranes of the TGN, at the trans-side 
of the Golgi stack (Fig. 12, white arrows). On the other hand, patient HLCs 
showed that both cisternae of the ER (Fig. 12 black arrows) and the Golgi 
membranes (Fig. 12, white arrows) contained mutant ATP7B protein. The graph 
in Fig. 12 shows that 35% of gold particles representing ATP7B signal were 
found in the Golgi and 65% in the ER. These results indicate that trafficking of 
ATP7B-H1069Q from the ER to the Golgi is hampered, but that the mutant 
maintains about 50% of the ability of the wt protein in reaching the Golgi 
complex. 
 
Figure 12. Confocal immunofluorescence analysis of HLCs immunolabeled 
for ATP7B and Golgin 97 (upper panels) or KDEL containing proteins 
(lower panels) as markers of Golgi complex and ER, respectively 
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DEGRADATION RATE  OF ATP7B 
HLCs derived from patient iPSCs showed lower expression of ATP7B-H1069Q 
(20% of control, graph in Fig. 13A). Furthermore, when HLCs obtained from 
control and patient iPSCs were incubated in the presence of the protein synthesis 
inhibitor cycloheximide, a clear reduction of ATP7B-H1069Q level was 
observed after 4 hours in patient HLCs, while no decrease was seen in the 
control (Fig. 13B). These results, taken together, strongly suggest that 
endogenously expressed ATP7B-H1069Q accumulates at lower level in patient 
HLCs because undergoes a faster degradation than the wt protein. 
Figure 13. Relative accumulation and degradation of ATP7B in HLCs 
obtained from control and patient iPSCs 
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ATP7B TRAIFFIC IN RESPONSE TO COPPER 
The ability of ATP7B to regulate copper levels heavily relies on copper-
dependent trafficking of the protein. In hepatic cells, elevated copper induces 
redistribution of ATP7B from the TGN to the endo/lysosomal compartments, 
where the transporter supports transient sequestration of excess copper into the 
organelle lumen. Mutations that disrupt copper-dependent trafficking of ATP7B 
prevent elimination of toxic copper from the cytosol. Therefore, to characterize 
the sensitivity of endogenous ATP7B-H1069Q to copper, we exposed both 
control and patient HLCs to CuSO4 for 2 h. As expected, confocal 
immunofluorescence analysis showed that in control cells copper triggers a 
redistribution of ATP7B from the Golgi to peripheral structures containing the 
endo/lysosomal marker LAMP1 (Fig. 14, arrows). Interestingly, patient HLCs 
exhibited identical relocation of the Golgi ATP7B pool towards endo/lysosomal 
compartments (Fig. 14, arrows). In summary, our observations suggest that 
ATP7B-H1069Q isogenically expressed in patient HLCs is functional in terms 
of copper-dependent trafficking. 
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Figure 14. Trafficking of ATP7B in response to high copper level in HLCs 
obtained from control and patient iPSCs.  
 
 
This research has been published in the following paper.  
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CHAPTER 4 
TO SEARCH NEW THERAPEUTIC OPTIONS USING MODERN 
STRATEGY FOR DRUG DISCOVERING: THE HYPOTHESIS DRIVEN 
STRATEGY 
Hypothesis 1 
In WD both serum lipoprotein alterations and fatty liver are common and share 
many pathophysiological mechanisms with lysosomal lipase activity deficiency 
(LAL-D). The earliest characteristic alterations of the liver pathology in WD 
include steatosis, which is sometimes indistinguishable from fatty liver due to 
metabolic syndrome. Recently it has been supposed that a genetic polymorphism 
in rs738409, in the patatin-like phospholipase domain (PNPLA3), may have a 
role in steatosis in WD patients. We could suppose that, as PNPLA3 
polymorphism, also LAL deficiency may be a contributing factor that influences 
progression of WD in a subgroup of patients.  
Study design 1 
A) To understand if lipid metabolism is compromised  in Wilson disease, we 
employed ATP7B knockout (ATP7B-KO) HepG2 cell line. ATP7B-KO and 
control HepG2 cells were incubated with Cu for 24h and their transcriptional 
responses to the metal were analyzed using QuantSeq 3’ mRNA sequencing, 
which allows very precise measurements of quantitative difference in gene 
involved in lipid metabolism expression. 
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B) We enrolled 20 patients followed at the Pediatric Liver Unit of University 
“Federico II” of Naples from 1986 to 2015, affected by Wilson Disease, 
diagnosed during childhood. Patients’ blood spots  for LAL activity assessment 
were collected with a standard procedure: first a peripheral venous blood sample 
was taken, then a drop of blood was collected falling on dedicated area of filter 
paper. To obtain dried blood spots, papers were kept first at ambient temperature 
for 24 hours. Samples were stored double-bagged with desiccant at − 20 °C and 
analyzed within 1 week of storage. LAL-A on DBS was determined by using 4-
methylumbelliferyl palmitate as substrate. As other lipases may interfere with 
LAL-A measurement, a specific LAL inhibitor known as Lalistat 2 was used. 
Total lipase activity was determined in absence and then in presence of the 
inhibitor: the difference between these results corresponds with LAL-A. The 
range of LAL-A was considered normal between 0,73 and 3,03 nmol/spot/h. 
According to Hamilton findings, LAL activity in homozygotes patients with 
LAL-deficiency was  <0.03 nmol/spot/h and in heterozygotes in the range 0.15–
0.40 nmol/spot/h. 7 In cases of LAL-A less than the lower limit of normal of 0.73 
nomol/spot/h, a second confirmation was obtained before proceeding to genetic 
analysis. DBS tests were performed in Bambino Gesù Hospital in Rome. 
Physicians analyzing LAL activity were unaware of clinical and biochemical 
characteristics of any enrolled patient. Molecular analysis: EDTA blood of 
patients with a LAL activity less than lower limit of normal was collected. Then 
each patient’s DNA was extracted from WBC using standard procedures and 
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subjected to an individual genotyping test. Molecular analysis was made by 
searching for E8SJM mutation in LIPA gene, using polymerase chain reaction 
(PCR) procedure. 
Results 1  
A) We observed in vitro that the expression of several genes involved in lipid 
metabolism (GO:0006629) was negatively regulated by Cu excess in both 
ATP7B-KO and control cells.  
B) In patients enrolled a low LAL -A at DBS was found in 6 patients with WD. 
None of these patients resulted affected by genetically determined LAL 
deficiency. WD patients with low LAL-A had BMI, T-C, triglycerides and uric 
acid levels higher then normal LAL-A WD patients .  
Table 4. BMI  and laboratory features of low LAL-A (N 6) and normal LAL-A (N 14) 
subjects within the group of patients with Wilson disease. 
PARAMETER 
 
WD LOW LAL-A 
SUBJECTS 
WD NORMAL LAL-
A SUBJECTS 
    P VALUE 
BMI kg/m2 
range 
26,4 + 3.7 
22,6-31,3 
21,9 + 7 
18-34,1 
 
 
        0,04* 
ALT UI/l 
range 
61,8 + 36 
25-109 
64,1 + 60 
16-242 
          0,9 
 
GGT UI/l 
range 
43.2 + 13 
14-77 
30.3 + 12 
6-178 
          0.5 
TRIGLYCERIDES 
mg/dl 
193.2 + 38.7 
86-327 
113,7+ 10.4 
53-210 
        0,01* 
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range 
T-C3  mg/dl 
range 
181.3+ 15 
131-217 
139.4 + 9 
102-224 
         0,02* 
 
LDL-C4  mg/dl 
range 
104,8 + 12.7 
70-148  
75.1 + 8.4 
50-150 
          0.08 
HDL-C5 mg/dl 
range 
                 35.8 + 5.2 
                24-53 
46.6 + 4.7 
33-78 
          0.21 
INSULIN mU/ml 
range 
14,52+ 5 
3,4-30,9 
18,39+ 5 
4,3-32,7 
          0,6 
 
HOMA INDEX 
range 
3,5 + 0.8 
0,56-6,38 
2,9+ 1.07 
0,91-8,83 
          0,7 
URIC ACID mg/dl 5.6 + 0.6 3.8 + 0.4          0,01* 
 
IMPLICATION OF THIS FINDING IN THERAPEUTC FIELD 
We could suppose that, as PNPLA3 polymorphism, also LAL deficiency may be 
a contributing factor that influences progression of WD in a subgroup of 
patients. This may explain, at least in part, the wide variability of phenotype and 
long-term course of liver disease among WD patients.  
Clearly it is difficult to hypothesize if the improvement in LAL activity may 
translate into a reduction of fatty liver content. Therefore we are far enough to 
speculate about  WD as a potential new target for the LAL enzyme-replacement. 
Some of this results hase been published in the following paper:  
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Hypothesis 2 
Psychiatric involvement (PI) in WD, despite being sneaky, are pretty relevant, 
with a prevalence of 30-100% among symptomatic patients.1 Missing data 
regarding PI in children with a liver disease at onset and treated for a long 
time. Furthermore, there is not any validated neuropsychiatric test that can 
identify the PI at pre-clinical stage. In adulthood the rate of treatment failure in 
WD is high.PI may influence treatment complicance.  
 
Study design 2 
We enrolled 18 children with a diagnosis of WD confirmed by liver histology or 
genetic analysis, without any neurologic involvement during the entire follow-
up and with a negative brain magnetic resonance (group 1). Mean age was 14 ± 
2.91 years old, with a mean age at the diagnosis of 6.16 ± 3.55 years and a mean 
treatment duration of 8 ± 4.73 years. Presentation was hepatic in 12 subjects 
(67%), while 6 patients (33%) were referred for family screening 
(presymptomatic). They didn’t have any neurologic involvement during the 
entire follow-up; in all brain magnetic resonance resulted negative. In all 
Raven’s Standard Progressive Matrices (SPM) documented the absence of 
cognitive disability. We consider two control groups matched for number, sex 
and age: (1) 20 healthy subjects (group 2);(2) 21 patients affected by an other 
hepatic chronic condition without psychiatric disorders which is comparable to 
WD for daily drugs administrations and annual visits requested (group 3). Each 
patient was evaluated in a screening phase with a caregiver report of behavioral 
and emotional problems (CBCL). CBCL is composed by three main scores 
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referred to: the internalizing scale (including anxious/depressed, withdrawn and 
somatic scores; T score int), to the externalizing scale (including rule-breaking 
and aggressive behavior scores; T score ext), to  the total problems scale 
(including T score INT+ T score Ext + social, thought, attention scores; T score 
tot). In a second phase, the patients who tested positive at CBCL scale (T score 
>64 in one of the three areas) were submitted to further evaluation using the 
semistructured diagnostic interview Kiddie Sads – Present and Lifetime Version 
(K-SADS-PL). To evaluate CBCL accuracy as screening tool in WD patients we 
performed a ROC analysis. 
Results 2 
CBCL in case group resulted pathologic for half of the subjects, among whom 
22% were not completely adherent to therapy (Figure 15).  
Figure 15. CBCL results in WD and control patients. 
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The CBCL test was pathologic or borderline: in 5 in the scale of 
anxious/depressed; in 5 in the scale of withdrawn; in 4 for somatic complaints; 
in 3 for the social problems; in 1 for thought problems; 1 for rule-breaking 
behaviors; 1 for aggressive behaviors. There’s no prevailing disorder 
(contingency analysis, p = 0.26, NS) depicting an heterogeneous spectrum of 
psychiatric manifestations. The K-SADS-PL was positive in 90 % of the group 1 
analyzed patients (positive at CBCL), in the following areas: psychotic disorder 
(12.5%), panic disorder (12.5%), social anxiety (25%), ADHD (37.5%), 
oppositional defiant disorder (25%), conduct disorder (12.5%).  
 
Figure 16. Type of psychiatric involvement in WD patients 
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In the 2 control groups CBCL was pathologic: in none of healthy subjects and in 
7% of subjects with other liver disease. Group 1 showed significantly higher T 
scores than group 2 and 3.  
Figure 17.  T score data in WD and control patiens 
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ROC analysis showed that CBCL is a good tool to screen psychiatric 
involvement in WD children without neurologic involvement (P: 0.009). The 
optimal diagnostic cut off value of T score is 66 (sensitivity: 100 %, 95%CI: 
73.5-100%; specificity: 83%, 95%CI:36-99%).  
Figure 18. ROC analysis to test accuracy of CBCL in WD patients 
 
 
IMPLICATION OF THIS FINDING IN THERAPEUTC FIELD 
PI in children with WD without neurologic involvement in treatment for a long 
time seems quite prevalent, higher than in patients with other chronic liver 
disease. CBCL seems a good diagnostic tool to identify PI in WD children at a 
preclinical stage. It seems important to screen WD population with CBCL to 
treat patients with non pharmacological or pharmacological specific 
intervention, to improve compliance to current therapy and reducing treatment 
failure in adolescence and adulthood.   
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CHAPTER 5 
 TO SEARCH NEW THERAPEUTIC OPTIONS USING MODERN 
STRATEGY FOR DRUG DISCOVERING: THE HIGH- THROUGHPUT  
SCREENING STRATEGY 
Understanding of metabolic mechanisms that either promote or counteract Cu 
toxicity in Wilson disease is of great importance to reveal potential targets for 
Wilson disease therapy. Cell utilize vast repertoire of tools to combat Cu 
toxicity. Relocation of efflux transporters ATP7A/B promotes Cu removal to the 
extracellular space. Another well-documented response to Cu includes either 
down-regulation or internalization of Cu influx transporter CTR1. Finally, Cu 
accumulation triggers up-regulation of metallothioneins or protein degradation 
components,which capture excess Cu ions or destroy proteins damaged by Cu, 
respectively. ATP7B-deficient cells fail to use most effective weapon (i.e. Cu 
efflux transporter) against Cu toxicity and, therefore, have to rely on alternative 
mechanisms trying to survive Cu overload. Indeed, increase in MT expression   
and to downregulation of Cu influx transporter CTR1  were documented in 
ATP7B-deficient hepatocytes.  
Autophagy has been recently noted as another mechanism with potential to 
counteract Cu toxicity. Autophagy activation has been shown to function as 
protective mechanism in response to anticancer Cu complexes, which induce 
oxidative stress in target tumor cells. Suppression of autophagy significantly 
promoted cytotoxicity of these Cu-based drugs. Unbelievably, the role of 
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autophagy in Wilson disease has never been investigated despite compelling 
evidences, which document impairment of red-ox balance in ATP7B-deficient 
hepatocytes. 
Study design  
To understand whether hepatic cells use autophagy to defend against Cu toxicity 
in Wilson disease, we employed ATP7B knockout (ATP7B-KO) HepG2 cell 
line. ATP7B-KO and control HepG2 cells were incubated with Cu for 24h and 
their transcriptional responses to the metal were analyzed using QuantSeq 3’ 
mRNA sequencing, which allows very precise measurements of quantitative 
difference in gene expression. 
Results 
LOSS OF ATP7B AND CU OVERLOAD TRIGGERS AUTOPHAGY 
ACTIVATION IN HEPATIC CELLS. 
We found that the exposure to Cu impacted the ATP7B-KO and control HepG2 
cells’ transcriptomes in a statistically significant manner: expression levels of 
1244 genes increased in the ATP7B-KO dataset, while control dataset exhibited 
induction of only 480 transcripts. Gene Ontology Enrichment Analysis (GOEA) 
on the lists of genes whose expression was altered in response to Cu 
revealedthat exposure of ATP7B-KO cells to Cu resulted in induction of 
autophagy-relevant genes indicating that autophagy may constitute an important 
part of transcriptional response to Cu in the case of ATP7B loss. To verify this 
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further, we first specified the subsets of genes differentially expressed in control 
cells and in ATP7B-KO cells and then subjected these sets to GOEA. GOEA 
revealed that autophagy was specifically and positively regulated in ATP7B-KO 
cells exposed to Cu. This finding was further mirrored by analysis of individual 
genes with annotated relevance to autophagy. ATP7B-KO cells exhibited 
specific and statistically significant (pValue=2,6E-05) activation of 103 
autophagic genes in response to Cu . 
Increase in expression of numerous autophagy genes suggests that autophagy 
might be activated in ATP7B-deficient cells in response to Cu build-up. To test 
whether this is the case, we analyzed distribution of the bona fide autophagy 
marker LC3 in control and ATP7B-KO cells at the steady-state conditions and 
upon exposure to Cu. Incubation with Cu caused an increase in number of LC3-
positive structures in both control and ATP7B-KO cells. However, the number 
of autophagosomes was significantly higher in ATP7B-deficient cells. In 
parallel, Western blot revealed stronger LC3 signal in both cell lines upon Cu 
treatment as well as an increase in amounts of lipidated LC3-II form, which is 
associated with autophagosome membrane) Importantly, ATP7B-KO cells were 
more susceptible to Cu-mediated induction of autophagy because even low Cu 
concentrations triggered substantial elevation of LC3 levels in these cells. This 
observation appears to be in line with transcriptomics data showing stronger 
activation of autophagy-associated genes in ATP7B-KO cells in response to Cu 
overload. Surprisingly, we found that ATP7B-KO cells exhibited higher number 
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of LC3-positive spots than parental HepG2 cells even without stimulation with 
Cu. Correspondingly, EM revealed that numerous autophagic structures 
appeared in the cytoplasm of cells lacking ATP7B, while in control cells 
autophagic vacuoles were scarce. Even phagophores (representing forming 
autophagosomes  were frequently observed in ATP7B-KO cells but were hardly 
detectable in control cells. This suggests that ATP7B loss leads to activation of 
autophagosome biogenesis. We also found that some structures with typical 
morphology of autophagosomes contained lysosomal marker LAMP1. 
Appearance of lysosomal marker in bona fide autophagosomes indicates that the 
fusion between autophagosomes and lysosomes normally happens in ATP7B-
deficient cells and that increase in autophagosome number does not occur due to 
block of fusion with lysosome organelles. Finally, activation of autophagy in 
ATP7B-deficient cells was also supported by Western blot, which displayed 
higher LC3 levels upon ATP7B depletion. Moreover, stimulation of autophagy 
by starvation led to faster rates of LC3 (and in particular LC3-II) increase in 
ATP7B-deficient cells. These observations indicate that lack of ATP7B and, 
hence, absence of efficient Cu efflux causes autophagy activation.  
Considering that during the course of Wilson disease hepatocytes are constantly 
exposed to increasing Cu amounts, we investigated whether the autophagy 
activation occurs in the liver of ATP7B-deficient LPP rats. LPP (Atp7b-/-) rats 
contain large deletion in Atp7b leading to the lack of detectable gene expression.  
Labeling of liver sections showed higher LC3 signal in hepatocytes of Atp7b-/- 
66 
 
rats, when compared to control animals. Correspondingly, EM detected 
numerous autophagic structures in the liver of Atp7b-deficient animals, while 
hepatocytes in control tissue rarely exhibited autophagosome or autolysosome 
profiles. Finally, we investigated liver biopsies from Wilson disease patients and 
found multiple autophagosomes in hepatocytes as well. For ethical reasons it 
was impossible to get any healthy human liver tissue for histological 
comparison. However, investigated patients had different levels of ATP7B 
function loss as revealed by serum levels of ceruloplasmin, a Cu-binding protein 
whose activity and stability relies on ATP7B-mediated metallation. Importantly, 
the patient 2 with mutations resulting in almost full loss of ATP7B catalytic 
activity exhibited higher number of autophagic structures in hepatocytes, 
compared to the patient 1 carrying only partial ATP7B dysfunction. In sum, 
above observations indicate that hepatic cells activate autophagy in response to 
ATP7B suppression and Cu overload.  
AUTOPHAGY OPERATES AS A PRO-SURVIVAL MECHANISM IN ATP7B-
DEFICIENT CELLS. 
To investigat how modulation of autophagy impacts resistance of ATP7B-
deficient cells to Cu cells were treated with 0.25 mM, 0.5 mM, and 1mM CuCl2 
for 24 h and their viability and apoptosis were evaluated. We observed that in 
the presence of high Cu ATP7B-ko cells changed their morphology, massively 
underwent apoptosis and died. The rate of Cu-mediated death in the population 
of ATP7B-deficient cells was significantly higher respect to control HepG2 
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cells. Then we stimulated autophagy by starving the cells with HBSS or 
suppressed autophagy by specific inhibitor spautin-1 and treated the cells with 
CuCl2 as indicated above. Starvation helped ATP7B-ko cells to survive in high 
Cu and significantly reduced their apoptosis. In contrast spautin-1 substantially 
accelerated death of ATP7B-deficient cells even at lowest (0.25 mM) Cu 
concentration. Next we analyzed whether overexpression of transcriptional 
activator of autophagy TFEB increases resistance of ATP7B-deficient cells to 
Cu. ATP7B-KO cells were transduced with helper-dependent adenoviruses 
carrying either TFEB or AFP (negative control) and exposed to Cu. TFEB 
overexpression significantly improved survival of ATP7B-deficient cells and 
dramatically reduced their apoptosis upon Cu overload. 
These findings suggest that autophagy acts as an important pro-survival 
mechanism, which protects ATP7B-deficient cells from Cu toxicity. 
IMPLICATION OF THIS FINDING IN THERAPEUTC FIELD 
Induction of autophagy has to be considered as a potential therapeutic approach 
to attenuate toxicities of metals in WD. 
This research is in press in the following paper.  
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CHAPTER 6 
FROM BENCH TO BEDSIDE: TO DEVELOP A CLINICAL TRIAL 
HSP70 represents an attractive target for ATP7B mutant correction and, hence, 
for normalization of copper homeostasis in WD.  Considering the importance of 
HSP70 for several vitally important processes such as protein folding and 
quality control, prevention of aggregation, transport and regulation of proteins, 
signal transduction and apoptosis, we attempted to find safe drugs that would 
inhibit HSP70 activity without significant impact on cell/organism health.  
Figure 19. Suppression of HSP70 reduces degradation and corrects 
localization of ATP7B-H1069Q  (courtesy of R. Polishchuck) 
 
 
To this end in collaboration with Telethon Institute of Genetics and Medicine 
(TIGEM) Bioinformatics Core we found several FDA-approved compounds, 
whose chemical structure resemble HSP70 inhibitor and tested whether such 
FDA-approved drugs modulate activity of HSP70 and rescue ATP7B-H1069Q 
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stability and function. Among 3 candidates that resemble HSP inhibitor, 
domperidone protected the ATP7B mutant from degradation and corrected the 
mutant localization at low µM concentrations in hepatics cells in vitro. These 
findings indicate domperidone as a potential drug for rescue of ATP7B function 
in patients carrying H1069Q mutation. This is a clear example of promising 
candidate for drug repurposing in rare disease. 
Figure 20. Domperidone rescues stability and localization of ATP7B-
H1069Q mutant (courtesy of R. Polishchuck). Panel A shows 3 FDA 
approved drugs with statistically significant structural similarity to HSP70 
inhibitor. Domperidone increases amounts of ATP7B-H1069Q even at the low 
µM concentrations (B, C) and corrects mutant localization from ER to Golgi (D) 
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Domperidone, a peripheral dopamine receptor antagonist with gastrokinetic and 
anti-emetic properties, has been marketed for over 35 years in more than 100 
countries for the relief of nausea and vomiting symptoms, epigastric sense of 
fullness, upper abdominal discomfort, and regurgitation of gastric contents in 
adults, and for the relief of nausea and vomiting symptoms in children 
(Reddymasu 2007). The highest dose approved globally for prescription use in 
adults is 20 mg up to four times daily, that is, up to 80 mg/day (European 
Medicines Agency-EMA-. Motilium Summary of Product Characteristics. 
Available at: http://www.ema. 
europa.eu/ema/index.jsp?curl1⁄4pages/medicines/human/re- 
ferrals/Motilium/human_referral_000090.jsp&mid1⁄4WC0- b01ac05805c516f 
Accessed 23 April 2013.). 
Considering that domperidone successfully passed through all biosafety test in 
preclinical and clinical studies and obtained FDA approval, it translation from 
the lab bench to eventual clinical use in WD should be relatively rapid once the 
effectiveness of this drug is confirmed in patients. In our in vitro experiments 
domperidone correct mutant localization at low µM concentrations. So we have 
planned to consider to test oral domperidone in adolescent and adult population 
(> 35 kg) using the therapeutic dosage cosidered safety (also according to 
Agenzia Italiana del Farmaco –AIFA. note 01/08/2014) of 10 mg three times a 
day (TID)  (according to European reports suggesting TID) before meals.  
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Duration of treatment is 4 consecutive weeks (Figure 4-study design). This time 
period should be sufficient to evaluate rescue of ATP7B-H1069Q mutant 
function on the basis of eventual increase in ceruloplasmin levels. 
Domperidone is approved and used to treat refractory symptoms of gastroparesis 
for long period. It is important to note that WD patients on zinc therapy have 
some adverse gastrintestinal events and sometimes it is necessary to recur to 
domperidone to control their symptoms related to therapy. In our experience 
domperidone showed a good safety profile in this condition.  
In the last few years, there has been increased awareness about domperidone 
side effects, especially cardiac adverse events (prolongation of the 
electrocardiogram (EKG) QTc interval thereby predisposing to cardiac 
arrhythmias). Recent studies  document oral domperidone safety at the 
therapeutic dosage under 30 mg/day for long period (>1 months) (Schey 2016; 
Biewenga 2015). The Pharmacovigilance Working Party  of the European 
Medicines Agency evaluated available preclinical and clinical data related to the 
cardiac safety of domperidone and concluded in October 2011 that the benefit-
risk remained positive (EMA. Monthly report from the EU Pharmacovigilance 
Working Party, PhVWP – Octo- ber 2011. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/10/WC5
00117061. pdf Accessed 23 April 2013). To further inform this position, 
European agencies requested that an ICH-E14 QT/QT corrected for heart rate 
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(QTc) study was conducted for labeled doses of domperidone, reporting the 
cardiac safety of domperidone. 
In summary, these clinical evaluations reveal a very low risk of cardiac side 
effects of domperidone and indicate this drug as a very safe candidate for 
repurposing in WD patients with H1069Q mutation. 
Project Workflow 
 
The main objective (Aim 1) of our research is to evaluate efficacy of such a  
new safe drug in WD as domperidone, which is able to act on the specific 
pathogenetic defect and then facilitate the transport of functional or partially 
damaged ATP7B  to the Golgi complex and cell membrane, where wild-type 
ATP7B normally operates.  
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Considering that domperidone effectively corrects localization of ATP7B-
H1069Q and protects this mutant from the degradation, we are going to enroll 
significant number of patients with this mutation in the study. Ceruloplasmin 
levels will be used as the main readout of the recovery of ATP7B-H1069Q 
function in domperidone-treated subjects. Ceruloplasmin synthesis requires 
ATP7B activity and undergoes degradation when does not receive copper from 
ATP7B. Ceruloplasmin level is not modified by standard treatment (zinc salts, 
chelators). Therefore we expect to observe increase in ceruloplasmin levels in 
ATP7B-H1069Q patients upon domperidone treatment. As a control group we 
intent to use WD patients with nonsense mutation in both alleles of ATP7B. 
These patients do not express any protein product of ATP7B and, hence, do not 
have any ATP7B protein, which could be corrected by domperidone. As a 
consequence, we expect that domperidone should not increase ceruloplamin 
levels in this control group of WD patients. 
Study design 
This prospective, randomized, double-blind, crossover, 36-month study will 
enroll patients from different centres.  
Study population is composed by WD patients carrying H1069Q mutation (on at 
least one allele) as case group and WD patients carrying nonsense mutation on 
both alleles as control group.  The study consists of three steps: (i) a screening 
phase, (ii) a double blind (for case group) treatment phase and (iii) a post-
treatment phase. 
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WD patients carrying H1069Q mutation (at least one allele mutated H1069Q) 
and nonsense mutation on both alleles will be evaluated for eligibility (screening 
period 8 months). At enrollment, case group patients  will be blinded randomly 
assigned (in a 1:1 ratio) to one of the two branches of treatment (placebo or 
domperidone). Randomization will be based on a computer-generated schedule. 
The treatment phase for case group includes 4 periods consisting of a treatment 
period of 4 weeks (domperidone for arm A versus placebo for arm B), a wash-
out period of 4 weeks, a second period of 4 weeks of treatment crossing the two 
groups (placebo for arm A and domperidone for arm B) and a final wash-out 
period of 4 weeks. The treatment phase for control group includes 2 periods 
consisting of a treatment period with domperidone for 4 weeks, a wash-out 
period of 4 week,s a second period of 4 weeks of placebo.  
Post-treatment follow-up will last 24 months.  
We consider as control negative group WD patients carrying nonsense mutation 
who need domperidone therapy for gastrintestinal symptoms related to zinc 
therapy.  
After signing the Informed Consent Form (ICF), patients will undergo a 60-day 
Screening Period during which the possible previous treatments with other 
domperidone compounds will be withdrawn (wash-out from previous 
treatment). Patients will undergo a serial weekly 12-lead electrocardiogram 
(EKGs).  If the EKG QTc interval is prolonged, domperidone is stopped.  
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Primary outcome measures include: 
- Ceruloplasmin levels  
- Urinary copper excretion in 24 h 
- Neurologic manifestations (including GAS Assesment Scale) 
- Psychiatric manifestations (neuropsychological tests) 
- Liver enzymes (AST, ALT, GGT) 
Secondary outcomes: 
- Assessment od upper gastrointestinal symptoms (PAGI-SYM) 
- Clinical Patients Grading Assessment Scale (CPGAS) 
- Fibrosis point at fibroscan 
- Neurophysiological studies (Transcranial magnetic stimulation) 
- Neuroimages (MRI with spectroscopy) 
- Metabolic parameters (glycemia, insulinemia, cholesterol, triglicerides) 
A multicenter, randomized, cross-over trial to assess the benefits of 
domperidone in Wilson Disease 
Domperidone (30 mg/day) Arm A 
Case group 
(WD “H1069Q patients”): 
Central randomization 
Arm B Placebo 
 4 weeks 
4 weeks 
4 weeks 
4 weeks 
4 weeks 
4 weeks 
Fig. 5 Study design 
Sample size estimation: 30  cases (15 arm A, 15 arm B) + 15 controls 
Generation of allocation sequence: central randomization by means of a IWRS (Interactive Web Response System)  
Allocation Concealment: Adequate 
Intention-to-treat analysis: Yes 
Screening period: 8 months 
Post-treatment follow-up: not blinded, 24 mo follow-up 
Funding: to be defined 
Wash-out 
4 weeks 
Wash-out 
4 weeks 
Visits 
1 2 3 4 5 
Control group 
(WD “nonsense patients”)  
Domperidone (30 mg/day) 
 4 weeks 
Wash-out 
4 weeks 
Placebo 
4 weeks 
Wash-out Placebo 
Domperidone (30 mg/day) Wash-out 
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CHAPTER 7 
     CONCLUSION 
Emerging strategies for WD cure foster new challenges that should be addressed 
by "precision" medicine, which takes in account the best available knowledge 
about disease mechanisms to establish approaches that yield an effective cure 
rate. Some compounds (tested in WD cell or animal models) seem to be close to 
translation into safe drugs and/or personalized treatments for WD patients.   
To establish whether and when these new therapies will be appropriate for 
clinical trials, a number of key requirements must be met. First, the particular 
reference population must be identified for treatment. It is likely that potential 
candidates for this population will include newly diagnosed people with 
relatively early disease, people with disease complications (e.g. liver failure or 
neurological presentations, for whom rapid mobilization of Cu could be 
beneficial), and those with intolerance for drug therapy. Considering the 
potential latency of some treatments before they become effective and the severe 
risks linked to suspension of preexisting treatment in WD patients, the 
combination of existing drugs and new therapeutic approaches to mobilize Cu 
will likely be the way forward for early clinical trials. Moreover, it will be 
important to define appropriate tests and effective endpoints that, in addition to 
clinical parameters, may be useful for demonstrating therapeutic efficacy, 
considering that drug monitoring necessitates use of noninvasive assays and 
biomarkers. In this context, the discovery of new biomarkers in WD will be of 
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great significance to enable new effective treatment. Advancing a WDcure will 
require an international cooperation to overcome the limited availability of 
affected patients who can be enrolled into clinical trials for development of new 
therapies. We hope that joint efforts between academia, industry, government 
and patient advocacy groups will allow for rapid progress and bring WD patient 
welfare to the forefront. 
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